Navigation Links
Starch Medical Launches Novel Plant Sourced Surgical Hemostatic Pad
Date:10/20/2009

SAN JOSE, Calif., Oct. 20 /PRNewswire/ -- Starch Medical Inc (SMI), a San Jose, CA-based medical device manufacturer, announces the first controlled clinical intro/launch of SealFoam(TM) Absorbable Polysaccharide Hemostat in the European Union and other major international markets. Introduction of SealFoam(TM) Absorbable Polysaccharide Hemostat will commence this month at the European Association of Cardio-Thoracic Surgeons congress in Vienna and in November at the MEDICA congress in Dusseldorf, Germany (booth #16E20).

SealFoam(TM) is the latest addition to the Absorbable Modified Polymer (AMP(TM)) product line and offers a hemostatic foam (pad) configuration for a wide range of surgical wounds. The ultra hydrophilic and adhesive properties of SealFoam(TM) are especially formulated to control oozing or profuse bleeding, and to minimize the possibility of re-bleeding. The pad may also be trimmed to suit the surgical procedure and is indicated for a diverse range of applications and unique wound contours.

AMP(TM) technology is a proprietary engineering process that modifies plant starch into biocompatible, absorbable, hemostatic polysaccharide particles. AMP(TM) particles have a molecular structure that rapidly absorbs water from blood, causing a high concentration of platelets, red blood cells and coagulation proteins which accelerate the physiologic clotting cascade at the bleeding site.

David Lang, President of SMI, states "SealFoam(TM) is currently the only available surgical hemostatic pad derived from plant starch without animal/human components. The superb efficacy offers surgeons a safe alternative for achieving hemostasis under various surgical conditions. We will introduce SealFoam(TM) through our global distribution network and potential partners during the 4th quarter of this year."

SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch Medical's proprietary, patent-pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace.

For additional information, distribution inquiries, and licensing options, please visit www.starchmedical.com.

Contact: Jane Chen of Starch Medical Inc, +1-408-428-9818, jane@starchmedical.com

SOURCE Starch Medical Inc


'/>"/>
SOURCE Starch Medical Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the ... and suppliers for its inaugural Member Conference at the Paris Hotel in Las ... the operational health of America’s healthcare providers. , The conference was highlighted by ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... and development solutions for drugs, biologics, consumer health and global clinical supply services, ... in Korea to support the company’s continued investment and strategic growth plans in ...
Breaking Medicine News(10 mins):